Skip to main navigation

Skip to Content

Menu

About Cerevel
Our Programs
Our Science
Investor & Media
Careers
- Working at Cerevel Therapeutics
- Open positions
Contact Us

News & Announcements

News & Announcements

Year

Mar 21, 2023

Cerevel Therapeutics to Present at the Stifel 2023 CNS Days

Mar 02, 2023

Cerevel Therapeutics to Present at the 43rd Annual Cowen Health Care Conference

Feb 22, 2023

Cerevel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Feb 01, 2023

Cerevel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates on Wednesday, February 22, 2023

Jan 09, 2023

Cerevel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference and Provide Pipeline Update

Jan 04, 2023

Cerevel Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Print

RSS Feeds

Email Alerts

Investor Contact

Search

Cerevel

About CerevelAbout Cerevel
Our ProgramsOur Programs
- Tavapadon
- CVL-871
- CVL-865
- CVL-231
- CVL-936
Our ScienceOur Science
- Our scientific strategy
- Our pipeline
Our ProgramsOur Programs
- Tavapadon
- CVL-871
- Darigabat
- CVL-231
- CVL-936
Investors & MediaInvestors & Media
- Overview
- News & Events
- Stock
- Financials
- Governance
- Resources
CareersCareers
- Working at Cerevel Therapeutics
- Open Positions
Contact Us

Facebook
Twitter
LinkedIn
YouTube

Cerevel

Terms of Use
Privacy Policy
FCOI
Early Access Program (EAP) Policy

© 2023 Cerevel Therapeutics

CEREVEL and the CEREVEL logo are trademarks of

Cerevel Therapeutics. All Rights Reserved.